Skip to main content

Sign in Register

Market DashboardMarkets, breadth and flows IndicesNSE & BSE benchmarks SectorsToday's rotation HeatmapSize = cap, colour = move BreadthAdvancers vs decliners FII/DIIInstitutional flows ValuationIs the market expensive?

SCREENER STOCKS FILINGS

Intelligence

Situations Conviction Broker Reports Earnings Deliveries Deals Corp. Actions

Discovery

Themes IPO Funds Community

PORTFOLIO MY AI

after·markets

Track what you own. Screen what you don't. India's market intelligence: screening, conviction scoring, and filing analysis, alive in real time.

Data: NSE & BSE

contact@aftermarkets.in

Markets

Market Dashboard
Screener
All Stocks
Heatmap
FII / DII

Research

Research hub
Filings
Conviction
Earnings
Broker Reports
Deliveries
Valuation
Deals
Themes
IPO Tracker
Funds & PMS

You

Portfolio
Trade Journal
Alerts
Watchlist
Get started

Company

About
Pricing
Learn
Developer / MCP
Terms
Privacy
Disclaimer

Operated by Chainlytics Advisory Services LLP.

© 2026 aftermarkets.in · Mumbai, IndiaInvestment in securities market are subject to market risks. Read all related documents carefully before investing.

GlaxoSmithKline Pharmaceuticals Limited

NSE: GLAXO · Healthcare · Pharmaceuticals · Market cap ₹42,885 Cr

₹2,531.50▴+6.70 (+0.27%)

· Prev close ₹2,524.80 · 52W ₹2,088–3,121

Day range for 8 Nov not in the price history yet · 6 Nov ₹2,489.30–2,544.80

Last 4 quarters: profit +123.9% on the 4 beforeShare price −8.4% in a month

GlaxoSmithKline Pharmaceuticals ₹2,531.50 ▴+0.27%

⇧⌘K

Company research

Overview
Profitability2
Growth5
Valuation4
Financial health5
Ownership5
Price momentum6
Filings & calls9
Company8

Every dataset is a tab inside its group. Search finds any of them, including old names such as “concall”.
Find a dataset: Ctrl/⌘ Shift K
Find another stock: Ctrl/⌘ K

GlaxoSmithKline Pharmaceuticals › Valuation

Valuation

Key figures Multiples & history Peer comparison Exit-multiple scenario

Loading selected research…

← PreviousGrowth · Triggers Next →Valuation · Multiples & history

: 37.9×; price ÷ last 4 quarters EPS
: 53.4×; FY19–26
: 39.4×; 5 listed peers
Price / book: 18.9×; fundamentals feed
EV / EBITDA: 23.4×; fundamentals feed
Dividend yield (feed): 2.01%; fundamentals feed
Earnings yield: 2.6%; 1 ÷ P/E

P/E at each year-end and todaydashed: peers' median

——63×48×262×79×13×54×53×42×38×

FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26Now

Peers' median 39.4×

Fiscal year-end readings only; intra-year highs and lows are not stored.

P/E, 6 listed peersranked, high to low

1Sai Life Sciences97.5×
2Gland Pharma41.5×
3Emcure Pharmaceuticals39.4×
4GlaxoSmithKline Pharmaceuticals37.9×
5IPCA Laboratories34.9×
6Ajanta Pharma33.0×

Median of the other 5: 39.4×

Exit-multiple scenario: set your own profit growth and exit P/E